While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.

The FLAIR trial provided the first clinical evidence that a time-limited combination of ibrutinib and venetoclax prevents the development of BTK resistance mutations. These mutations were observed in patients receiving continuous single-agent BTK inhibitor therapy, supporting a key theoretical advantage of time-limited combination approaches.

Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.

Mesutoclax's key advantages over the established BCL-2 inhibitor venetoclax are practical. It is designed to minimize prolonged myelosuppression and, critically, avoids significant drug-drug interactions with common antifungals. This simplifies real-world management for elderly patients on multiple medications, addressing a major logistical headache for clinicians.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

While pirtobrutinib was already used off-label per NCCN guidelines, its official FDA approval provides a government-sanctioned alternative, forcing a direct decision between it and a venetoclax-based regimen for patients relapsing on a prior BTK inhibitor.

While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.